Literature DB >> 9516978

Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

G Fontanini1, M De Laurentiis, S Vignati, S Chinè, M Lucchi, V Silvestri, A Mussi, S De Placido, G Tortora, A R Bianco, W Gullick, C A Angeletti, G Bevilacqua, F Ciardiello.   

Abstract

We have determined the expression of transforming growth factor alpha (TGF alpha), amphiregulin (AR), CRIPTO, the epidermal growth factor receptor (EGFR), erbB-2, erbB-3, and tumor angiogenesis in a series of 195 patients with stage I-IIIA non-small cell lung cancer (NSCLC) treated with radical surgery to define their usefulness as prognostic indicators of survival. A variable degree of specific staining in cancer cells was observed for the three growth factors and for the three growth factor receptors in the majority of NSCLC patients. A statistically significant association between overexpression of TGF alpha, AR, and CRIPTO was observed. Enhanced expression of AR was significantly correlated with enhanced expression of erbB-2 and advanced T-stage. A direct association was also detected for overexpression of TGF alpha and of erbB-2 or erbB-3, respectively. Sex, tumor size, nodal status, stage, microvessel count, as a measure of neovascularization, and AR overexpression significantly correlated with overall survival at univariate analysis. In a Cox multivariate analysis, the only characteristics with an independent prognostic effect on OAS were microvessel count [relative hazard (RH), 6.61; P < 0.00001), nodal status (RH, 1.59; P = 0.0013), and AR overexpression (RH, 1.72; P = 0.02). These results suggest that evaluation of neoangiogenesis and of certain growth factors, such as AR, can be useful in addition to conventional pathological staging to select high-risk NSCLC patients who may benefit from post-surgical systemic therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516978

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

1.  Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues.

Authors:  Amy L McDoniels-Silvers; Gary D Stoner; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

2.  Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.

Authors:  Goro Oshima; Johan Wennerberg; Takashi Yamatodani; Elisabeth Kjellén; Hiroyuki Mineta; Anders Johnsson; Lars Ekblad
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-23       Impact factor: 4.553

Review 3.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

4.  The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Authors:  Yong-Feng Yu; Zhi-Wei Chen; Zi-Ming Li; Zong-Hai Li; Shun Lu
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

5.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

Authors:  Gillian Bethune; Drew Bethune; Neale Ridgway; Zhaolin Xu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

6.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

7.  Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Authors:  Kimio Yonesaka; Kreshnik Zejnullahu; Neal Lindeman; Alison J Homes; David M Jackman; Feng Zhao; Andrew M Rogers; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer.

Authors:  Hye-Sook Seo; Diane D Liu; B Nebiyou Bekele; Mi-Kyoung Kim; Katherine Pisters; Scott M Lippman; Ignacio I Wistuba; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

9.  EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.

Authors:  Chad A Reade; Apar Kishor Ganti
Journal:  Biologics       Date:  2009-07-13

10.  Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy.

Authors:  Chuangzhou Rao; Qiongge Hu; Jianhua Ma; Jian Li; Chen Zhang; Li Shen; Qichun Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.